Changes in the <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> during lipid - lowering treatment with diet , clofibrate and niceritrol . Reduction of the <font color="red">proportion_1</font> <font color="red">of_1</font> <font color="red">linoleate_1</font> by clofibrate but not by niceritrol . 
<br>
<br> <font color="red">The_1</font> <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> has been studied during lipid - lowering treatment of 95 patients with atherosclerotic disease . During the first two months of the trial only a diet was prescribed . During the ensuing two months either clofibrate or niceritrol , a nicotinic acid ester , was added in a randomized order . During the last two months the second drug was added . The combined treatment with diet , clofibrate and niceritrol caused highly significant <font color="red">serum_1</font> <font color="red">lipid_1</font> reductions . <font color="red">The_1</font> <font color="red">fatty_1</font> <font color="red">acid_1</font> <font color="red">composition_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">plasma_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> was determined in samples from each trial period to measure the degree of dietary adherence . During dietary treatment the relative <font color="red">content_2</font> <font color="red">of_2</font> <font color="red">saturated_4</font> <font color="red">and_4</font> <font color="red">monounsaturated_4</font> <font color="red">fatty_4</font> <font color="red">acids_4</font> <font color="red">secreased_1</font> <font color="red">and_1</font> <font color="red">the_1</font> <font color="red">polyunsaturated_4</font> <font color="red">fatty_4</font> <font color="red">acids_4</font> <font color="red">increased_1</font> with an <font color="red">increasing_1</font> <font color="red">ratio_2</font> <font color="red">between_2</font> <font color="red">pulyunsaturated_2</font> <font color="red">and_2</font> <font color="red">saturated_2</font> <font color="red">fatty_2</font> <font color="red">acids_2</font> <font color="red">(_1</font> <font color="red">P_1</font> <font color="red">/_1</font> <font color="red">S_1</font> <font color="red">ratio_1</font> <font color="red">)_1</font> in the cholesterol esters and triglycerides . Only <font color="red">minor_1</font> <font color="red">changes_1</font> <font color="red">were_1</font> <font color="red">seen_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">phospholipids_2</font> <font color="red">._2</font> The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major changes of the <font color="red">fatty_3</font> <font color="red">acid_3</font> <font color="red">composition_3</font> <font color="red">._3</font> Clofibrate treatment coincided with increasing <font color="red">amounts_1</font> <font color="red">of_1</font> <font color="red">monounsaturated_3</font> <font color="red">fatty_3</font> <font color="red">acids_3</font> <font color="red">,_3</font> especially <font color="red">oleate_1</font> ( 18 : 1 ) , in the <font color="red">cholesterol_1</font> <font color="red">esters_1</font> <font color="red">,_1</font> <font color="red">triglycerides_3</font> <font color="red">and_3</font> <font color="red">phospholipids_3</font> <font color="red">while_1</font> <font color="red">there_1</font> <font color="red">were_1</font> <font color="red">significant_1</font> <font color="red">reductions_1</font> <font color="red">of_1</font> <font color="red">the_1</font> <font color="red">content_3</font> <font color="red">of_3</font> <font color="red">linoleic_4</font> <font color="red">(_1</font> <font color="red">18_1</font> <font color="red">:_1</font> <font color="red">2_1</font> <font color="red">)_1</font> <font color="red">acid_2</font> in both the cholesterol esters and triglycerides . The 18 : 2/18 : 1 ratio <font color="red">decreased_1</font> <font color="red">significantly_1</font> <font color="red">in_1</font> <font color="red">all_1</font> <font color="red">the_1</font> <font color="red">lipid_1</font> <font color="red">esters_1</font> <font color="red">analyzed_1</font> <font color="red">._1</font> However , the <font color="red">P_2</font> <font color="red">/_2</font> <font color="red">S_2</font> <font color="red">ratio_2</font> was not significantly affected , partly because the relative <font color="red">content_1</font> <font color="red">of_1</font> <font color="red">saturated_2</font> <font color="red">fatty_2</font> <font color="red">acids_2</font> also tended to decrease during clofibrate treatment . It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a <font color="red">change_1</font> <font color="red">from_1</font> <font color="red">polyunsaturated_2</font> <font color="red">to_2</font> <font color="red">monounsaturated_2</font> <font color="red">fatty_2</font> <font color="red">acids_2</font> <font color="red">in_2</font> <font color="red">the_2</font> <font color="red">plasma_2</font> <font color="red">lipid_2</font> <font color="red">esters_2</font> <font color="red">but_1</font> <font color="red">does_1</font> <font color="red">not_1</font> <font color="red">significantly_1</font> <font color="red">effect_1</font> <font color="red">the_1</font> <font color="red">ratio_2</font> <font color="red">between_1</font> <font color="red">polyunsaturated_1</font> <font color="red">and_1</font> <font color="red">saturated_1</font> <font color="red">fatty_1</font> <font color="red">acids_1</font> <font color="red">._1</font> The fatty <font color="red">acid_1</font> <font color="red">changes_1</font> caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .